An observational study in Differentiated Thyroid Cancer, Thyroid Cancer and Levothyroxine, sponsored by University Medical Center Groningen. Not yet recruiting at 2 sites in Netherlands. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-02-10.
Sponsored by University Medical Center Groningen · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Thyroid Neoplasms with a site in Netherlands — 6 open to participants now, 8 under way, 1 of them phase 3. Thyroid Neoplasms · Netherlands.
Among the 28 studies in Thyroid Neoplasms with a site in Netherlands, this one is one of 2 that started in 2026, is one of 4 observational ones, and was the 28th registered.
785 studies on the registry are indexed under Thyroid Neoplasms; 203 are open to participants now.
Browse Thyroid Neoplasms studies →6 of the 28 studies in Thyroid Neoplasms with a site in Netherlands are open now. Recruiting first, the newest first:
Radboud University Medical Center · Sites in Netherlands
Ages 18+
University Medical Center Groningen · Sites in Netherlands
Ages 18–75
Leiden University Medical Center · Sites in Netherlands
Ages 18+
Turning Point Therapeutics, Inc. · Sites in Netherlands, United States, Australia and 16 more countries
Ages 12+
University Medical Center Groningen · Sites in Netherlands
Ages 65+
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 151 Thyroid Neoplasms studies recruiting now, 95 (63%) set no upper age limit and 27 (18%) stop at 75 or younger; 36 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 8 · Phase 3 4 · Phase 4 3
First in 2004; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 178 across 241 observational studies indexed under Thyroid Neoplasms.
Median enrollment 76 across the 24 interventional studies, 71 across the 4 observational. Of the 17 that completed or were terminated, 8 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 28 have an industry lead sponsor. The 10 most frequent:
University Medical Center Groningen is the lead sponsor of 627 studies on the registry; 175 are open to participants now.
University Medical Center Groningen has 5 studies filed under Thyroid Neoplasms — fewer than ten, so there is no comparison to draw.
1 of the studies in Thyroid Neoplasms with a site in Netherlands that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07485569Radboud University Medical CenterDrug Repurposing in Thyroid Carcinoma: a Feasibility Trial | 2027-10-01 |
Add it to your calendar (.ics) → With an account.
Among the 28 studies in Thyroid Neoplasms with a site in Netherlands, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will be a multicentre prospective cohort study on TH-substitution after thyroid hormone withdrawal preceding radioiodine treatment.
While treatment with L-T4 after TH-withdrawal is widely used in DTC patients to suppress TSH and improve hypothyroid symptoms, the value of L-T3 addition in initiation of TH treatment has not been evaluated in this context. Lifelong monotherapy with L-T3 should not be preferred over L-T4 yet, short-term use of L-T3 to initiate TH-supplementation can be safely implemented. We hypothesize that initial treatment with L-T4+L-T3 combination treatment can have a more direct effect on TSH-levels and earlier relieve of hypothyroid symptoms resulting in a better QoL. We will conduct a prospective cohort study comparing the initiation of TH-supplementation after TH-withdrawal in two cohorts of DTC patients: patients receiving L-T4+LT3 with a gradually decrease of L-T3 dose in time, and patients receiving L-T4 only. We will compare potency to suppress TSH, effect on QoL and effects on thyroid- and cardiovascular parameters. Patients (18-75 years) diagnosed with high-risk DTC after TH-withdrawal will be eligible for inclusion. The primary objective is to compare the proportion of patients reaching target TSH-levels after two weeks of substitution with L-T3 or L-T4.
Secondary objectives are to compare the effects of L-T4+L-T3 or L-T4 in the first 3 months of treatment on serum thyroid parameters TSH and Tg, quality of life, and cardiovascular parameters
This study will include patients with a histologically confirmed high-risk DTC, men and women aged 18-75 years. Patients have to be prepared to RAI with TH-withdrawal and treated according to the ATA guidelines.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
L-T4+L-T3 combination according to local protocol.
Drug: Cytomel (liothyronine)
L-T4 monotherapy according to local protocol.
Drug: Euthyrox (levothyroxine)
Euthyrox (levothyroxine sodium tablets; L-T4) is a thyromimetic synthetic drug identical to T4. Patients will recieve levothyroxine (euthyrox) in a dose of 2 μg × kg body weight / day.
Cytomel (liothyronine sodium tablets; L-T3) is a thyromimetic synthetic drug identical to T3. The patients in this cohort recieve L-T4+L-T3 combination therapy. The L-T4 dose will be 2 μg × kg body weight / day, equal to the dose in the other interventional arm. L-T3 will be added twice daily from the first day of combination treatment, in dosages gradually decreasing from 25 ug 2/day to 5 ug 2/day over a time span of 3 weeks after which L-T3 is stopped.
TSH after two weeks of TH substitution
The percentage of patients reaching target TSH (\<0.5 mU/L) after two weeks of L-T3+L-T4 substitution compared to patients with L-T4-substitution.
Time frame: Before and after 2 weeks of TH-substitution
TSH (mU/L)
The % of decrease of serum thyroid parameters TSH after 1, 2, 4, 6, and 12 weeks of TH-substitution.
Time frame: Before and after 1, 2, 4, 6, and 12 weeks of TH-substitution.
Thyroglobulin (Tg; ng/mL)
The % of decrease of serum thyroid parameters Tg after 1, 2, 4, 6, and 12 weeks of TH-substitution. Tg is a precursor of T3 and T4 and is a measurement for remaining thyroid (cancer) cells. Tg-levels are affected by TSH and therefore, we expect by reducing TSH-levels to also reduce Tg levels. Consecutive Tg-measurements in this study act as a secondary measure for TH substitution. Since Tg-values between patients variable, we will use the % decrease instead of absolute values.
Time frame: Before and after 1, 2, 4, 6, and 12 weeks of TH-substitution
QoL in patients treated with L-T3 or L-T4
Quality of life will be assessed using standardized QoL questionnaires for thyroid- and thyroid cancer patient reported outcome. Our aim is to compare improvement of hypothyroid symptoms after initiation of therapy, and evaluate whether sings of hyperthyroidism and possible overtreatment are present. We will use the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 (core measure QoL questionnaire) in combination with the THYCA-QoL (additional thyroid cancer-specific part).
Time frame: Before and after 2, 6, and 12 weeks of TH-substitution
Heart rate (HR; bpm)
Cardiovascular parameters will be assessed during visits to the outpatient clinic before initiation of TH-substitution (during hypothyroidism) and after 6 weeks of TH-treatment. Patients will be compared intra- and interindividually.
Time frame: Before and after 6 and 12 weeks of TH-substitution
Blood pressure (BP; mmHg)
Cardiovascular parameters will be assessed during visits to the outpatient clinic before initiation of TH-substitution (during hypothyroidism) and after 6 and 12 weeks of TH-treatment. Patients will be compared intra- and interindividually.
Time frame: Before and after 6 and 12 weeks of TH-substitution
Plan to share: No — Handling of personal data complies with the General Data Protection Regulation (GDPR; in Dutch: De uitvoeringswet algemene verorderning gegevensbescherming [UAVG]). Encoded data will be kept for 15 years after closure of the study and can only be used for ancillary studies after strict approval of the study protocol by the project leader (dr. W. Zandee).
No publications or documents are linked to this record.
Start is estimated for Sep 2026; primary completion for Mar 2028, 18 months later.
Of 103 non-industry observational studies under Thyroid Neoplasms, half reached primary completion within 71 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 311. This study's planned 18 months is below that.
Counting every sponsor, half of 112 studies reached it within 63 months; a quarter within 26 and three quarters within 311.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Medical Center Groningen →